Education
About Us
Working with TipRanks
Follow Us
Zynex Inc (ZYXI)
:ZYXI
ZYXI Stock Chart & Stats
$1.33
-$0.09(-1.11%)
At close: 4:00 PM EST
$1.33
-$0.09(-1.11%)
Day’s Range― - ―
52-Week Range$1.23 - $9.42
Previous CloseN/A
Volume7.23K
Average Volume (3M)83.04K
Market Cap
$40.30M
Enterprise Value$132.98M
Total Cash (Recent Filing)$17.54M
Total Debt (Recent Filing)$72.46M
Price to Earnings (P/E)24.1
Beta1.60
Next Earnings
Oct 23, 2025EPS Estimate
-0.17Last Dividend Ex-Date
Jan 05, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding30,297,441
10 Day Avg. Volume73,409
30 Day Avg. Volume83,043
Financial Highlights & Ratios
PEG Ratio-1.28
Price to Book (P/B)7.16
Price to Sales (P/S)1.33
P/FCF Ratio21.07
Enterprise Value/Market Cap3.30
Enterprise Value/Revenue0.92
Enterprise Value/Gross Profit1.22
Enterprise Value/Ebitda-8.59
Forecast
1Y Price Target
$2.60Price Target Upside95.49% Upside
Rating ConsensusHold
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Leadership ChangeSteven Dyson, with over 25 years of experience in the medical technology sector, has been appointed as CEO to refocus Zynex's business strategy and return it to a strong growth trajectory.
Market ExpansionNiCO, if cleared by the FDA, would allow Zynex to enter the $2.8 billion pulse oximetry market with differentiating precision and accuracy in hospital and non-hospital settings.
Bears Say
Potential DilutionPotential dilution risk is noted as a concern for Zynex's stock value.
Regulatory RisksRisks include slower-than-anticipated revenue growth due to competition and inability to secure regulatory clearance for other medical devices.
Revenue DeclineTotal revenue was $22.3M, representing 55% YoY decline and missing our projection of $27.0M.
Zynex News
ZYXI FAQ
What was Zynex Inc’s price range in the past 12 months?
Zynex Inc lowest stock price was $1.23 and its highest was $9.42 in the past 12 months.
What is Zynex Inc’s market cap?
Zynex Inc’s market cap is $40.30M.
When is Zynex Inc’s upcoming earnings report date?
Zynex Inc’s upcoming earnings report date is Oct 23, 2025 which is in 4 days.
How were Zynex Inc’s earnings last quarter?
Zynex Inc released its earnings results on Jul 31, 2025. The company reported -$0.66 earnings per share for the quarter, missing the consensus estimate of -$0.197 by -$0.463.
Is Zynex Inc overvalued?
According to Wall Street analysts Zynex Inc’s price is currently Undervalued.
Does Zynex Inc pay dividends?
Zynex Inc pays a Notavailable dividend of $0.091 which represents an annual dividend yield of N/A. See more information on Zynex Inc dividends here
What is Zynex Inc’s EPS estimate?
Zynex Inc’s EPS estimate is -0.17.
How many shares outstanding does Zynex Inc have?
Zynex Inc has 30,297,441 shares outstanding.
What happened to Zynex Inc’s price movement after its last earnings report?
Zynex Inc reported an EPS of -$0.66 in its last earnings report, missing expectations of -$0.197. Following the earnings report the stock price went down -43.498%.
Which hedge fund is a major shareholder of Zynex Inc?
Currently, no hedge funds are holding shares in ZYXI
Zynex Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.60 (95.49% Upside)
$2.60 (95.49% Upside)
Blogger Sentiment
Bullish
ZYXI Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 6.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.27%
12-Months-Change
Fundamentals
Return on Equity
-168.22%
Trailing 12-Months
Asset Growth
-29.51%
Trailing 12-Months
Company Description
Zynex Inc
Zynex, Inc. (NASDAQ: ZYXI) is a medical technology company based in the United States that specializes in developing and manufacturing non-invasive medical devices for pain management and rehabilitation. The company focuses on innovative electrotherapy products, particularly its NexWave and NeuroMove devices, which are designed to provide relief from chronic pain and assist in physical rehabilitation. Zynex operates primarily in the healthcare sector, catering to both patients and medical professionals, with a commitment to enhancing quality of life through advanced medical technologies.
ZYXI Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call highlighted significant challenges, including a sharp revenue decline and ongoing issues with TRICARE payment suspension. However, the company's efforts to reduce costs, improve cash flow, and advance new products like the NiCO pulse oximeter provide some positive outlook for future growth. The appointment of a new CEO also signals a strategic refocus. Despite these efforts, the challenges currently outweigh the positive developments.View all ZYXI earnings summariesZYXI Stock 12 Month Forecast
Average Price Target
$2.60
▲(95.49% Upside)
Technical Analysis
Henry Schein
―
Owens & Minor
―
Prestige Consumer Healthcare
―
Guardian Pharmacy Services, Inc. Class A
―
Wellgistics Health Inc
―
Ownership Overview
43.09% Insiders
4.45% Mutual Funds
0.25% Other Institutional Investors
49.25% Public Companies and
Individual Investors